首页> Leukemia research> Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

导出 OA

翻译打印收藏纠错

第一作者： Vu H,Duong

第一单位： University of Maryland Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: vduong@umm.edu.

作者： Vu H,Duong ^[1] ; Maria R,Baer ^[2] ; Franklin,Hendrick ^[3] ; Sheila R,Weiss ^[3] ; Masayo,Sato ^[3] ; Amer M,Zeidan ^[4] ; Steven D,Gore ^[4] ; Amy J,Davidoff ^[5]

作者单位： University of Maryland Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: vduong@umm.edu. ^[1] University of Maryland Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. ^[2] Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA. ^[3] Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. ^[4] Agency for Healthcare Research and Quality, Rockville, MD, USA. ^[5]

关键词 Anemia Comparative effectiveness Erythropoiesis-stimulating agents Myelodysplastic syndromes